Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma

NCT03389802 is registered in ClinicalTrials.gov with Pediatric Brain Tumor Consortium as lead sponsor.

NCT NCT03389802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03389802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Lead sponsor
Pediatric Brain Tumor Consortium
Phase
Phase 1
Overall status
Completed
Start date
March 1, 2018
Completion date
July 20, 2026
Enrollment
32 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cns primary tumor, not otherwise specified (nos), diffuse intrinsic pontine gliomas (dipg), ependymoma, not otherwise specified (nos), glioblastoma multiforme, high-grade astrocytoma not otherwise specified (nos), medulloblastoma